7:00 PM-7:05 PM Program Overview
7:05 PM-7:35 PM The Importance of Molecular and Cytogenetic Testing in AML
Case Discussion 1: Targeting Antigens in AML—New Advances in Antibody–Drug Conjugates and Other Antibody-Based Therapies
7:35 PM-8:00 PM Case Discussion 2: Overcoming Treatment Challenges in Patients With Newly Diagnosed AML
8:00 PM-8:15 PM Case Discussion 3: Available and Emerging Treatment Options in FLT3-Mutant AML
8:15 PM-8:35 PM Case Discussion 4: Available and Emerging Treatment Options in IDH-Mutant AML
8:35 PM-8:50 PM Exploring New Therapeutic Frontiers in AML—What Are the Emerging Molecular Targets?
8:50 PM-9:00 PM Closing Remarks and Audience Question and Answer Session
Date / Time
Radisson Blu Aqua Hotel, Chicago
Farhad Ravandi, MD
Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Gary J. Schiller, MD
Director, Hematological Malignancy/Stem Cell Transplantation
Professor, Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
The goal of this activity is to improve the competence of physicians in applying the latest practice-changing developments to the clinical care of patients with acute myeloid leukemia.
This program is intended for physicians and other healthcare providers who care for patients with acute myeloid leukemia.
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
- Assess the available evidence to optimally integrate antibody–drug conjugates and other antibody-based therapies in AML
- Plan evidence-based therapeutic strategies using novel formulations and refinements of conventional chemotherapy
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
- Manage treatment-related toxicities associated with novel therapeutics
- Identify patients with AML who may benefit from enrollment on clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.